2019
DOI: 10.2174/1389450120666190618123846
|View full text |Cite
|
Sign up to set email alerts
|

PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence

Abstract: Background: Phosphoinositide 3-kinase (PI3Ks) is a member of intracellular lipid kinases and involved in the regulation of cellular proliferation, differentiation and survival. Overexpression of the PI3K/Akt/mTOR signalling has been reported in various forms of cancers, especially in colorectal cancers (CRC). Due to their significant roles in the initiation and progression events of colorectal cancer, they are recognized as a striking therapeutic target. Objective: The present review is aimed to provide a de… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
152
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 210 publications
(153 citation statements)
references
References 101 publications
1
152
0
Order By: Relevance
“…The phosphoinositide 3-kinase (PI3K)/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) signaling axis is a crucial signaling pathway in both physiological and pathological conditions, and has been evidenced to interact with a variety of pathways, such as mitogen-activated protein kinases (MAPKs), hypoxia-inducible factor, Ras, Notch and Wnt/β-catenin, which are responsible for cell proliferation, survival, and drug resistance [2][3][4][5]. Accordingly, PI3K/Akt/mTOR signaling is a core pathway responsible for tumor progression and drug resistance and appears to be a potential target in various cancer treatments, including CRPC [6][7][8][9].…”
Section: Introductionmentioning
confidence: 99%
“…The phosphoinositide 3-kinase (PI3K)/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) signaling axis is a crucial signaling pathway in both physiological and pathological conditions, and has been evidenced to interact with a variety of pathways, such as mitogen-activated protein kinases (MAPKs), hypoxia-inducible factor, Ras, Notch and Wnt/β-catenin, which are responsible for cell proliferation, survival, and drug resistance [2][3][4][5]. Accordingly, PI3K/Akt/mTOR signaling is a core pathway responsible for tumor progression and drug resistance and appears to be a potential target in various cancer treatments, including CRPC [6][7][8][9].…”
Section: Introductionmentioning
confidence: 99%
“…For instance, PI3K/Akt/mTOR can promote cell invasion and migration in CC and has potential to be a therapeutic target. [35] Thus, it is necessary to investigate these predictions, which are likely to offer novel therapeutic targets in CC.…”
Section: Discussionmentioning
confidence: 99%
“…AKT can increase the expression level of cyclin D1 and other factors, and can directly activate the CDK1 protein, so that cells can pass through cell cycle checkpoints to accelerate cell proliferation. Also, AKT regulates the function of members of the Bcl-2 family, inhibits the formation of dimers of bcl-2, and promotes the inactivation of the pro-apoptotic factor, Bax, to inhibit cell apoptosis [28,29]. Inhibition of the AKT pathway is an important approach to anticancer therapy [30,31].…”
Section: Discussionmentioning
confidence: 99%